New hope for aggressive lung cancer: combo therapy enters phase 3 trial
Disease control
Not yet recruiting
This phase 3 trial tests whether a new drug, BL-M14D1, combined with the immunotherapy atezolizumab works better than standard treatment for people with advanced small cell lung cancer that has spread. About 550 adults who have not had prior treatment will be randomly assigned to…
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC